THE POLICY EDGE
Policy Bites

7 March 2026

8th Jan Aushadhi Diwas – Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

SDG 3: Good Health and Well-being | SDG 10: Reduced Inequalities | SDG 12: Responsible Consumption and Production

Ministry of Chemicals and Fertilizers MoCF | Ministry of Health and Family Welfare MoHFW | Department of Pharmaceuticals DoPs

On March 7, 2026, India celebrated the 8th "Jan Aushadhi Diwas," marking the significant impact of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) in providing high-quality generic medicines at affordable prices. Operated by the PMBI, the scheme has expanded to over 14,000 Jan Aushadhi Kendras across the country, significantly reducing the out-of-pocket expenditure for citizens by offering medicines at 50% to 90% lower costs than branded alternatives.

The 2026 celebrations, themed around "Sasti Bhi, Achhi Bhi" (Affordable and Quality), highlighted the introduction of new product categories, including nutraceuticals and medical devices, to ensure comprehensive healthcare coverage. By maintaining a high-fidelity supply chain and stringent quality testing at NABL-accredited labs, the PMBJP acts as a primary mechanic for achieving universal health coverage and ensuring that life-saving drugs are accessible to the last mile of society.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Key Pillars of PMBJP (2026 Status)

  • Network Expansion: Surpassing the milestone of 14,000 functional Kendras, covering nearly every district in India to improve physical accessibility.

  • Cost Efficiency: Maintaining a price structure where generic drugs are priced at a fraction (10% to 50%) of the market rate for branded medicines.

  • Quality Assurance Framework: Ensuring every batch of medicine undergoes rigorous testing at NABL-accredited laboratories before distribution.

  • Product Basket Diversification: Expanding the offering to include over 2,000 medicines and 300 surgical items, covering major therapeutic groups like cardiovascular, anti-diabetic, and oncology.

  • IT-Enabled Supply Chain: Utilizing a centralized warehouse management system and the "Jan Aushadhi Sugam" mobile app to track real-time stock availability and locate nearby stores.

  • Women's Health Initiative: Distributing "Jan Aushadhi Suvidha" biodegradable sanitary napkins at a nominal cost of ₹1 per pad to promote menstrual hygiene.

What is the "Jan Aushadhi Diwas"? Jan Aushadhi Diwas is an annual celebration held on March 7th to raise awareness about the benefits of generic medicines and the PMBJP scheme. It serves as an operational platform for the government to engage with beneficiaries, health professionals, and store owners to gather feedback and promote the "Jan Aushadhi" brand. The week-long activities leading up to the day—such as "Jan Aushadhi Pratigya Yatra" and health camps—operate on the mechanical theory that increasing public trust in generic drugs is a prerequisite for reducing the national healthcare cost burden.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Policy Relevance: India’s Affordable Healthcare Strategy

  • Operationalizing Generic Adoption: The success of PMBJP acts as a primary mechanic for the Ministry of Health to shift prescribing patterns toward generics, significantly lowering the financial barrier to chronic disease management.

  • Internalizing Rural Health Access: The expansion of Kendras in aspirational districts provides a functional framework for the National Health Mission to integrate affordable medicine supply with primary healthcare centers.

  • Bypassing Monopoly Pricing: By providing high-quality alternatives, the scheme acts as a mechanical shield for consumers against the premium pricing of multi-national pharmaceutical brands.

  • Link to "Atmanirbhar Bharat": PMBJP supports domestic pharmaceutical manufacturers by providing a massive, guaranteed market for generic production, fostering self-reliance in the health sector.

Relevant Question for Policy Stakeholders: In what ways can the government utilize NABL testing data to mechanically counter misinformation regarding the efficacy of generic medicines compared to branded versions?


Follow the Full Release Here: 8th Jan Aushadhi Diwas - March 7, 2026

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Rethinking Public Policy Through Insight | Inquiry | Impact

Opinion • Grassroots Voices • Policymakers Perspectives • Expert Analysis • Policy Briefs